vRe - dVise: Self-administration devices for injectable therapies

vRe

Reusable variable-dose pen injector

vRe

Reusable variable-dose pen injector

vRe

Reusable variable-dose pen injector

For chronic therapies with frequent, flexible dosing

Indications

Diabetes

GLP-1 / Weight Management

Technical specifications

Max dose

0.80 ml

Dose increment

0.01 ml

Primary container

Standard 3 ml cartridge according to ISO 11608-3

Plunger

8.5 mm or 11.5 mm

Needles

Compatible with standard needles according to ISO 11608-2

Pre-validated packages in development

dVise is developing regulatory-ready, pre-validated packages compatible with selected molecules. Biosimilars and close analogues can often follow the same route. For molecules or use cases outside the pre-validated paths, the platform is tuned to your molecule.

Pre-validated packages

Regulatory-ready device platforms in development for selected molecules including testing, documentation to give your team a shorter path to adopt.

Semaglutide (GLP-1)

Expected availability: end of 2026 / start of 2027

Custom adaptations

For molecules or use cases outside the pre-validated paths, the platform is tuned to your molecule.

hello@dvise.com